全球科学服务领域的领导者——赛默飞世尔科技公司（Thermo Fisher Scientific）正在正投入巨资扩大其在蛋白质研究领域的影响力。2023年10月17日，赛默飞宣布收购蛋白质组学分析设备和服务提供商Olink。 赛默飞同意以31亿美元的价格收购Olink在纳斯达克的股票，每股价格为26美元，这比Olink之前的收盘价高出约74%。这笔收购包括吸收Olink的1.43亿美元净现金，以及该公司在波士顿、东京和上海的国际业务。Olink的全球员工总数为667人，其中包括224名商业团队成员。 赛默飞总裁兼首席执行官 Marc Casper 在声明中表示，收购Olink凸显了蛋白质组学在公司的客户不断推进生命科学研究和精准医疗方面的深远影响。 Olink专有的临近延伸分析（PEA）技术旨在为实验室以前安装的qPCR仪器和下一代测序仪带来高通量蛋白质分析。该检测方法建立在一个包含5300多个蛋白质生物标志物目标的文库上，并已在约1400份科学论文中使用。 值得一提的是，2023年10月4日，Nature 期刊同期发表了3篇研究论文，使用了Olink的Explore平台和英国生物样本

XPHOZAH has been approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy XPHOZAH blocks the absorption of phosphate with a single tablet taken twice daily Commercial launch underway with product expected to be available in November Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to dis

将为中国患者带来基因治疗新选择 2023年10月17日 信念医药集团（以下简称信念医药）与武田中国今日宣布达成独家合作协议，信念医药授权武田中国在中国内地、中国香港和中国澳门负责其在研产品BBM-H901注射液的商业化经营。双方将结合各自领域的优势和资源，加速推动该产品的商业化进程，助力B型血友病患者获得创新治疗新选择，共同促进基因疗法的产业发展。 信念医药联合创始人、董事长兼首席科学家肖啸博士表示："信念医药专注深耕前沿基因治疗领域，产品管线广泛涵盖罕见病与常见病，致力填补大量未被满足的临床需求。BBM-H901注射液是信念医药自主研发和生产的重磅产品之一，亦是国内首个进入注册临床试验的B型血友病的腺相关病毒（AAV）基因治疗药物。非常高兴在2023上海国际生物医药产业周期间，信念医药与武田中国达成此次战略合作，相信依托信念医药扎实的临床开发实力以及武田中国强大的商业化能力，必将助力双方进一步夯实管线策略及市场布局，强强联手，互信合作，聚力将更多创新治疗方案带给广大中国患者。" B型血友病是一种遗传性凝血功能障碍疾病，由于患者血液中缺乏凝血因子Ⅸ（FIX）所致，其特点为反复的、自发性

Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree 15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-r

Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration In preclinical studies, administration of the dual-action CAR T cells followed by administration of a CMV vaccine successfully eradicated HIV, including from latent reservoirs Triplex is currently the subject of multiple ongoing clinical tr

- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform (“PPMP”) applied to select and develop

近期，已有58同城、和睦家、秦淮数据、凹凸科技等多家美股中概股公司完成或计划私有化退市。10月12日，纳斯达克精准医疗龙头、中概股公司泛生子(NASDAQ:GTH)发布公告，宣布已正式签署私有化合并协议。 根据协议，参与此次交易的买方团包括中金康瑞医疗基金、Wealth Strategy Holding Limited、无锡国联集团、建信(北京)投资基金管理有限责任公司、无锡惠宏赢康投资合伙企业（有限合伙）等。 协议显示，每股普通股收购价格为0.272美元，每股美国存托股票（“ADS”，每股ADS代表5股普通股）收购价格为1.36美元。此项交易的价格比泛生子宣布收到私有化要约前的最后一个交易日，溢价约为15%；与宣布收到私有化要约的前30个交易日平均收盘价相比，该报价溢价21%。截至2023年10月11日，即公告发布前最后一个交易日，溢价42%。公告称，私有化交易预计于2024年一季度完成。 中概股的选项，私有化退市突围 中概股的“暴风骤雨”还在持续。像知名中概股京东的股价一直在探寻新低。截至2023年9月21日，京东市值从高点已经跌去七成。 自2019年以来，先是美国监管机构发布

- Enrollment ex-China Expected to be Completed in November 2023 – - Enrollment in China Expected to Commence this Quarter - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided an update on its Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in patients with acute myeloid leukemia

Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into an acquisition agreement dated October 12, 2023 (the "Agreement") with Wolf Acquisitions 1.0 Corp. ("Wolf"), an arm's length private British Columbia corporation, and 1443885 B.C. Ltd. ("Subco"), a wholly-owned subsidiary of the Company, pursuant to which Optimind will acquire all of the issued and outstanding common shares of Wolf (each, a "Wolf Share") by way of "three-cornered"

Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acqui